GHRP-2 10mg – Growth Hormone Releasing Peptide for Strength

GHRP-2 (Growth Hormone Releasing Peptide-2), also known as Pralmorelin or KP-102, is a potent synthetic hexapeptide and a member of the growth hormone secretagogue (GHS) class. It acts as a selective agonist of the ghrelin receptor (GHS-R1a), mimicking the action of the natural “hunger hormone” ghrelin to stimulate the pituitary gland’s release of endogenous growth hormone (GH).

Key Benefits and Potential Uses

GHRP-2 is primarily researched and utilized in contexts involving growth hormone stimulation, including:

• Diagnostic assessment of growth hormone deficiency (GHD) in children and adults (approved in some regions like Japan under the brand GHRP Kaken 100 for diagnostic purposes).
• Supporting increased GH and IGF-1 levels, which may contribute to improved muscle protein synthesis, enhanced recovery, and better body composition.
• Potential applications in promoting lean muscle growth, fat metabolism, and recovery from intense physical activity or injury.
• Studies in animal models and limited human trials suggest benefits for growth performance in cases of growth retardation, increased appetite/food intake, and support for metabolic health.
• Often explored in regenerative and performance wellness settings to encourage natural GH pulsatile release rather than exogenous hormone administration.

It works through multiple mechanisms:

• Binds to ghrelin receptors in the pituitary and hypothalamus to trigger GH secretion in a pulsatile, more physiological manner.
• May inhibit somatostatin (a GH suppressor) while amplifying GH-releasing pathways, including calcium-dependent signaling.
• Increases hunger and food intake (orexigenic effect), which can support caloric needs during muscle-building or recovery phases (though less pronounced than with GHRP-6 in some comparisons).

Administration Options

GHRP-2 is typically available as a lyophilized powder for reconstitution and subcutaneous injection (most common in research and wellness use). It has also been studied via intravenous, intranasal, and oral routes. Dosing in research settings often starts low (e.g., 1–3 μg/kg) and may be administered 1–3 times daily, with gradual titration under supervision to assess response and tolerance.